Gts Securities LLC Liquidia Corp Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$8.9 - $14.11 $705,770 - $1.12 Million	79,300 Added 785.15%	89,400 $894,000
Q2 2024 Aug 14, 2024	SELL	$11.96 - $15.71 $111,228 - $146,103	-9,300 Reduced 47.94%	10,100 $121,000
Q1 2024 May 15, 2024	SELL	$11.35 - $16.73 $175,925 - $259,315	-15,500 Reduced 44.41%	19,400 $286,000
Q4 2023 Feb 14, 2024	BUY	$5.77 - $12.19 $81,357 - $171,879	14,100 Added 67.79%	34,900 $419,000
Q3 2023 Nov 15, 2023	BUY	$6.27 - $8.15 $130,415 - $169,520	20,800 New	20,800 $131,000

171

44.3M

1.55M

1.52M

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $745M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.